Products - Skin cancer | Topic | NICE

Showing 41 products

Date | Sort by Title

Status: PublishedRemove ‘Status: Published’ filter

Suspected cancer recognition and referral
Product type:
Pathway
Last updated:
26 March 2020
Melanoma
Product type:
Pathway
Last updated:
13 November 2019
Skin cancer
Product type:
Pathway
Last updated:
6 August 2019
Sunlight exposure: risks and benefits
Product type:
Pathway
Last updated:
1 June 2017
Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
7 August 2019
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
20 March 2019
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
27 February 2019
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA558)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
23 January 2019
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
19 December 2018
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
17 October 2018
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
11 April 2018
Vismodegib for treating basal cell carcinoma (TA489)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
22 November 2017
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
12 September 2017
Published date:
25 November 2015
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
12 September 2017
Published date:
7 October 2015
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
31 August 2017
Suspected cancer: recognition and referral (NG12)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
26 July 2017
Published date:
23 June 2015
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
26 October 2016
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
28 September 2016
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
27 July 2016
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
22 June 2016
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
18 February 2016
Skin cancer prevention (PH32)
Product type:
Guidance
Programme:
Public health guideline
Last updated:
9 February 2016
Published date:
26 January 2011
Sunlight exposure: risks and benefits (NG34)
Product type:
Guidance
Programme:
NICE guideline
Published date:
9 February 2016
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)
Product type:
Guidance
Programme:
Diagnostics guidance
Published date:
11 November 2015
Melanoma: assessment and management (NG14)
Product type:
Guidance
Programme:
NICE guideline
Published date:
29 July 2015
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 January 2015
Published date:
12 December 2012
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
22 October 2014
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
23 July 2014
Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published date:
26 February 2014
Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published date:
27 March 2013
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
12 December 2012
Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)
Product type:
Guidance
Programme:
Medical technologies guidance
Published date:
25 July 2011
Endoscopic radical inguinal lymphadenectomy (IPG398)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published date:
22 June 2011
Improving outcomes for people with skin tumours including melanoma (CSG8)
Product type:
Guidance
Programme:
Cancer service guideline
Last updated:
25 May 2010
Published date:
22 February 2006
Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) (IPG155)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published date:
22 February 2006
Suspected cancer (QS124)
Product type:
Quality standard
Last updated:
5 December 2017
Published date:
30 June 2016
Skin cancer (QS130)
Product type:
Quality standard
Published date:
21 September 2016
GatewayC: Improving early detection of cancer through e-learning for primary care
Product type:
Shared learning
Published date:
31 January 2019
Overcoming the challenges of implementing the new NICE guidance for suspected cancer: recognition and referral
Product type:
Shared learning
Published date:
8 January 2017
A primary school sunlight exposure policy
Product type:
Shared learning
Published date:
1 July 2016
Setting up an effective and efficient sentinel lymph node biopsy service for malignant melanoma within the NHS
Product type:
Shared learning
Published date:
29 July 2015